Correlation Between 4D Molecular and Citius Oncology,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both 4D Molecular and Citius Oncology, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 4D Molecular and Citius Oncology, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between 4D Molecular Therapeutics and Citius Oncology,, you can compare the effects of market volatilities on 4D Molecular and Citius Oncology, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 4D Molecular with a short position of Citius Oncology,. Check out your portfolio center. Please also check ongoing floating volatility patterns of 4D Molecular and Citius Oncology,.

Diversification Opportunities for 4D Molecular and Citius Oncology,

0.87
  Correlation Coefficient

Very poor diversification

The 3 months correlation between FDMT and Citius is 0.87. Overlapping area represents the amount of risk that can be diversified away by holding 4D Molecular Therapeutics and Citius Oncology, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Citius Oncology, and 4D Molecular is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 4D Molecular Therapeutics are associated (or correlated) with Citius Oncology,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Citius Oncology, has no effect on the direction of 4D Molecular i.e., 4D Molecular and Citius Oncology, go up and down completely randomly.

Pair Corralation between 4D Molecular and Citius Oncology,

Given the investment horizon of 90 days 4D Molecular Therapeutics is expected to generate 0.44 times more return on investment than Citius Oncology,. However, 4D Molecular Therapeutics is 2.25 times less risky than Citius Oncology,. It trades about -0.13 of its potential returns per unit of risk. Citius Oncology, is currently generating about -0.2 per unit of risk. If you would invest  2,473  in 4D Molecular Therapeutics on September 1, 2024 and sell it today you would lose (1,689) from holding 4D Molecular Therapeutics or give up 68.3% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy61.9%
ValuesDaily Returns

4D Molecular Therapeutics  vs.  Citius Oncology,

 Performance 
       Timeline  
4D Molecular Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days 4D Molecular Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Citius Oncology, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Citius Oncology, has generated negative risk-adjusted returns adding no value to investors with long positions. Even with abnormal performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

4D Molecular and Citius Oncology, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with 4D Molecular and Citius Oncology,

The main advantage of trading using opposite 4D Molecular and Citius Oncology, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 4D Molecular position performs unexpectedly, Citius Oncology, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will offset losses from the drop in Citius Oncology,'s long position.
The idea behind 4D Molecular Therapeutics and Citius Oncology, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Complementary Tools

Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities